Compare AXTI & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AXTI | NEO |
|---|---|---|
| Founded | 1986 | 2001 |
| Country | United States | United States |
| Employees | N/A | 2500 |
| Industry | Semiconductors | Precision Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 1998 | 2008 |
| Metric | AXTI | NEO |
|---|---|---|
| Price | $32.54 | $8.87 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $24.50 | $11.14 |
| AVG Volume (30 Days) | ★ 6.9M | 2.0M |
| Earning Date | 05-15-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 35.71 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $99,361,000.00 | N/A |
| Revenue This Year | $44.70 | $10.63 |
| Revenue Next Year | $42.23 | $9.73 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 31.09 | N/A |
| 52 Week Low | $1.13 | $4.72 |
| 52 Week High | $47.00 | $13.74 |
| Indicator | AXTI | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 53.36 | 26.03 |
| Support Level | $2.56 | $7.20 |
| Resistance Level | N/A | $8.89 |
| Average True Range (ATR) | 4.95 | 0.68 |
| MACD | 0.23 | -0.09 |
| Stochastic Oscillator | 42.77 | 4.21 |
AXT Inc is a developer and producer of compound and single element semiconductor substrates, also known as wafers. The dominant substrates used in producing semiconductor chips and other electronic circuits are made from silicon. It is engaged in the design, development, manufacture, and distribution of high-performance compound semiconductor substrates and the sale of materials. The company provides alternative or specialty materials in the form of substrates or wafers, including compound and single-element substrates. Its compound substrates combine indium with phosphorous or gallium with arsenic. Geographically firm has its business presence across the region of Europe, Japan, Taiwan, China, North America, and the Asia Pacific from which China derives its maximum revenue to the company.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.